Skip to content

Analgesic Effect of Breastmilk for Procedural Pain in Preterm Infants

Breastmilk or Oral Sucrose Solution in Preterm Neonates for Procedural Pain: a Randomized, Controlled Study

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00908401
Acronym
BMoS
Enrollment
42
Registered
2009-05-25
Start date
2009-04-30
Completion date
2009-07-31
Last updated
2009-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Procedural Pain

Keywords

breastmilk, oral sucrose, analgesia, preterm neonates, Neonates

Brief summary

Hypothesis: Breastmilk has a more powerful analgesic effect than oral sucrose to avoid procedural pain in preterm neonates. The objective is to test this hypothesis in a randomized, controlled study using a standardized and validated pain scale (DAN). The sample size is 21 preterm infants in each two groups. The main end point is a reduction of the risk to have a DAN superior to 1 from 80% with oral sucrose to 40% with breastmilk.

Interventions

Breastmilk: 0.2 ml

oral sucrose: 0.2 ml one time 1 minute before the painful procedure with a pacifier

Sponsors

Centre Hospitalier Intercommunal Creteil
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Days to 10 Days
Healthy volunteers
No

Inclusion criteria

* preterm neonates born before 27 and 29+6 weeks GA * blood sampling procedure * obtention of parental consent

Exclusion criteria

* congenital malformation * intravenous continuous analgesia * contraindications to feed * high grade intracerebral hemorrhage

Design outcomes

Primary

MeasureTime frame
Decrement from 80 to 40% of frequency of DAN's scale score superior to 1 using breastmilk instead of oral sucroseOne time during day 3 or 4 then day 7 to 10

Countries

France

Contacts

Primary ContactElodie Zana, MD
Elodie.Zana@chicreteil.fr+33 1 45 17 54 39

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026